Chris Schott
Stock Analyst at JP Morgan
(3.30)
# 1,031
Out of 4,734 analysts
122
Total ratings
51.9%
Success rate
1.38%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $171.56 | +16.58% | 2 | Nov 13, 2024 | |
| GILD Gilead Sciences | Maintains: Overweight | $100 → $105 | $91.84 | +14.33% | 3 | Nov 7, 2024 | |
| BIIB Biogen | Maintains: Neutral | $220 → $210 | $140.55 | +49.41% | 3 | Nov 4, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,200 → $1,150 | $681.58 | +68.73% | 5 | Oct 24, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Neutral | $16 → $18 | $21.92 | -17.88% | 15 | Oct 21, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $630 → $575 | $419.26 | +37.15% | 7 | Oct 11, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $165.89 | +38.65% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $1,050 → $1,100 | $725.72 | +51.57% | 20 | Sep 13, 2024 | |
| OGN Organon & Co. | Downgrades: Underweight | $18 → $20 | $15.74 | +27.06% | 2 | Sep 6, 2024 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Neutral | $9 | $8.26 | +8.96% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $41 | $23.84 | +71.98% | 11 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $30.75 | +36.59% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $272.11 | -0.78% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $26.30 | +29.28% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $97.92 | +27.66% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $11.30 | +23.89% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.39 | +691.37% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $12.02 | +66.39% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.44 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $56.29 | +38.57% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $7.25 | +13,003.45% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.06 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $22.36 | +123.61% | 3 | Nov 2, 2018 |
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $171.56
Upside: +16.58%
Gilead Sciences
Nov 7, 2024
Maintains: Overweight
Price Target: $100 → $105
Current: $91.84
Upside: +14.33%
Biogen
Nov 4, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $140.55
Upside: +49.41%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Overweight
Price Target: $1,200 → $1,150
Current: $681.58
Upside: +68.73%
Teva Pharmaceutical
Oct 21, 2024
Maintains: Neutral
Price Target: $16 → $18
Current: $21.92
Upside: -17.88%
IDEXX Laboratories
Oct 11, 2024
Maintains: Overweight
Price Target: $630 → $575
Current: $419.26
Upside: +37.15%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $165.89
Upside: +38.65%
Eli Lilly
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $725.72
Upside: +51.57%
Organon & Co.
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $15.74
Upside: +27.06%
Amneal Pharmaceuticals
Sep 6, 2024
Upgrades: Neutral
Price Target: $9
Current: $8.26
Upside: +8.96%
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $23.84
Upside: +71.98%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $30.75
Upside: +36.59%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $272.11
Upside: -0.78%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $26.30
Upside: +29.28%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $97.92
Upside: +27.66%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $11.30
Upside: +23.89%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.39
Upside: +691.37%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $12.02
Upside: +66.39%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.44
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $56.29
Upside: +38.57%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $7.25
Upside: +13,003.45%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.06
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $22.36
Upside: +123.61%